Validation of HB-EGF and amphiregulin as targets for human cancer therapy

Fusanori Yotsumoto, hiroshi yagi, Satoshi Suzuki, Eiji Oki, Hiroshi Tsujioka, Touru Hachisuga, Kenzo Sonoda, Tatsuhiko Kawarabayashi, Eisuke Mekada, Shingo Miyamoto

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Aberrant expression levels of epidermal growth factor receptor (EGFR) and its cognate ligands have been recognized as one of the causes of cancer progression. To investigate the validity of EGFR ligands as targets for cancer therapy, we examined the expression of EGFR ligands and in vitro anti-tumor effects of small interference RNA (siRNA) for EGFR ligands in various cancer cells. HB-EGF expression was dominantly elevated in ovarian, gastric, and breast cancer, melanoma and glioblastoma cells, whereas amphiregulin was primarily expressed in pancreatic, colon, and prostate cancer, renal cell carcinoma and cholangiocarcinoma cells. Transfection of siRNAs for HB-EGF or amphiregulin into these cells significantly increased the numbers of apoptotic cells with attenuation of EGFR and ERK activation. In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy. These results suggest that HB-EGF and amphiregulin are promising targets for cancer therapy.

Original languageEnglish
Pages (from-to)555-561
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume365
Issue number3
DOIs
Publication statusPublished - Jan 18 2008

Fingerprint

Epidermal Growth Factor Receptor
Ligands
Cells
Neoplasms
Therapeutics
Cholangiocarcinoma
Glioblastoma
RNA Interference
Pancreatic Neoplasms
Renal Cell Carcinoma
Ovarian Neoplasms
Colonic Neoplasms
Stomach Neoplasms
Transfection
Heparin-binding EGF-like Growth Factor
Amphiregulin
Tumors
Melanoma
Lung Neoplasms
Prostatic Neoplasms

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Validation of HB-EGF and amphiregulin as targets for human cancer therapy. / Yotsumoto, Fusanori; yagi, hiroshi; Suzuki, Satoshi; Oki, Eiji; Tsujioka, Hiroshi; Hachisuga, Touru; Sonoda, Kenzo; Kawarabayashi, Tatsuhiko; Mekada, Eisuke; Miyamoto, Shingo.

In: Biochemical and Biophysical Research Communications, Vol. 365, No. 3, 18.01.2008, p. 555-561.

Research output: Contribution to journalArticle

Yotsumoto, F, yagi, H, Suzuki, S, Oki, E, Tsujioka, H, Hachisuga, T, Sonoda, K, Kawarabayashi, T, Mekada, E & Miyamoto, S 2008, 'Validation of HB-EGF and amphiregulin as targets for human cancer therapy', Biochemical and Biophysical Research Communications, vol. 365, no. 3, pp. 555-561. https://doi.org/10.1016/j.bbrc.2007.11.015
Yotsumoto, Fusanori ; yagi, hiroshi ; Suzuki, Satoshi ; Oki, Eiji ; Tsujioka, Hiroshi ; Hachisuga, Touru ; Sonoda, Kenzo ; Kawarabayashi, Tatsuhiko ; Mekada, Eisuke ; Miyamoto, Shingo. / Validation of HB-EGF and amphiregulin as targets for human cancer therapy. In: Biochemical and Biophysical Research Communications. 2008 ; Vol. 365, No. 3. pp. 555-561.
@article{437dddff73124129b256a357b71e2a74,
title = "Validation of HB-EGF and amphiregulin as targets for human cancer therapy",
abstract = "Aberrant expression levels of epidermal growth factor receptor (EGFR) and its cognate ligands have been recognized as one of the causes of cancer progression. To investigate the validity of EGFR ligands as targets for cancer therapy, we examined the expression of EGFR ligands and in vitro anti-tumor effects of small interference RNA (siRNA) for EGFR ligands in various cancer cells. HB-EGF expression was dominantly elevated in ovarian, gastric, and breast cancer, melanoma and glioblastoma cells, whereas amphiregulin was primarily expressed in pancreatic, colon, and prostate cancer, renal cell carcinoma and cholangiocarcinoma cells. Transfection of siRNAs for HB-EGF or amphiregulin into these cells significantly increased the numbers of apoptotic cells with attenuation of EGFR and ERK activation. In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy. These results suggest that HB-EGF and amphiregulin are promising targets for cancer therapy.",
author = "Fusanori Yotsumoto and hiroshi yagi and Satoshi Suzuki and Eiji Oki and Hiroshi Tsujioka and Touru Hachisuga and Kenzo Sonoda and Tatsuhiko Kawarabayashi and Eisuke Mekada and Shingo Miyamoto",
year = "2008",
month = "1",
day = "18",
doi = "10.1016/j.bbrc.2007.11.015",
language = "English",
volume = "365",
pages = "555--561",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Validation of HB-EGF and amphiregulin as targets for human cancer therapy

AU - Yotsumoto, Fusanori

AU - yagi, hiroshi

AU - Suzuki, Satoshi

AU - Oki, Eiji

AU - Tsujioka, Hiroshi

AU - Hachisuga, Touru

AU - Sonoda, Kenzo

AU - Kawarabayashi, Tatsuhiko

AU - Mekada, Eisuke

AU - Miyamoto, Shingo

PY - 2008/1/18

Y1 - 2008/1/18

N2 - Aberrant expression levels of epidermal growth factor receptor (EGFR) and its cognate ligands have been recognized as one of the causes of cancer progression. To investigate the validity of EGFR ligands as targets for cancer therapy, we examined the expression of EGFR ligands and in vitro anti-tumor effects of small interference RNA (siRNA) for EGFR ligands in various cancer cells. HB-EGF expression was dominantly elevated in ovarian, gastric, and breast cancer, melanoma and glioblastoma cells, whereas amphiregulin was primarily expressed in pancreatic, colon, and prostate cancer, renal cell carcinoma and cholangiocarcinoma cells. Transfection of siRNAs for HB-EGF or amphiregulin into these cells significantly increased the numbers of apoptotic cells with attenuation of EGFR and ERK activation. In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy. These results suggest that HB-EGF and amphiregulin are promising targets for cancer therapy.

AB - Aberrant expression levels of epidermal growth factor receptor (EGFR) and its cognate ligands have been recognized as one of the causes of cancer progression. To investigate the validity of EGFR ligands as targets for cancer therapy, we examined the expression of EGFR ligands and in vitro anti-tumor effects of small interference RNA (siRNA) for EGFR ligands in various cancer cells. HB-EGF expression was dominantly elevated in ovarian, gastric, and breast cancer, melanoma and glioblastoma cells, whereas amphiregulin was primarily expressed in pancreatic, colon, and prostate cancer, renal cell carcinoma and cholangiocarcinoma cells. Transfection of siRNAs for HB-EGF or amphiregulin into these cells significantly increased the numbers of apoptotic cells with attenuation of EGFR and ERK activation. In lung cancer cells, any EGFR ligand was not recognized as a validated target for cancer therapy. These results suggest that HB-EGF and amphiregulin are promising targets for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=36549072385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549072385&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2007.11.015

DO - 10.1016/j.bbrc.2007.11.015

M3 - Article

C2 - 18023415

AN - SCOPUS:36549072385

VL - 365

SP - 555

EP - 561

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -